Pre-existing adenovirus immunity modifies a complex mixed th1 and th2 cytokine response to an ad5/hiv-1 vaccine candidate in humans

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Pine, Samuel O ^a,b   Kublin, James G ^b   Hammer, Scott M ^c   Borgerding, Joleen ^b   Huang, Yunda ^b   Casimiro, Danilo R ^d   McElrath, M Juliana ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; MRKAD5 HIV 1 GAG VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; GAG PROTEIN;

ADENOVIRUS; ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; MALE; MULTICENTER STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; BIOSYNTHESIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETICS; IMMUNOLOGY; MIDDLE AGED; TH1 CELL; TH2 CELL;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOVIRIDAE; ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, GAG; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS;

EID: 79954595049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018526     Document Type: Article

References (58)

1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
3. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, et al. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46: 1769-1781.
4. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2008) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
5. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18: 1213-1216.
6. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, et al. (2004) Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15: 293-304.
7. Perreau M, Pantaleo G, Kremer EJ, (2008) Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205: 2717-2725.
8. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106: 19940-19945.
9. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, et al. (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75.
10. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450.
11. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, et al. (2005) HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 102: 7239-7244.
12. Harari A, Petitpierre S, Vallelian F, Pantaleo G, (2004) Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103: 966-972.
13. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
14. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323: 39-54.
15. Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, et al. (2010) Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. In press.
16. Chapman BS, Thayer RM, Vincent KA, Haigwood NL, (1991) Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res 19: 3979-3986.
17. Chroboczek J, Bieber F, Jacrot B, (1992) The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186: 280-285.
18. Youil R, Toner TJ, Su Q, Casimiro D, Shiver JW, et al. (2003) Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses. Hum Gene Ther 14: 1017-1034.
19. Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, et al. (2007) Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses 23: 86-92.
20. Dubey DP, Alper CA, Mirza NM, Awdeh Z, Yunis EJ, (1994) Polymorphic Hh genes in the HLA-B(C) region control natural killer cell frequency and activity. J Exp Med 179: 1193-1203.
21. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, et al. (2006) Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24: 6893-6904.
22. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957.
23. Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, et al. (2009) Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 83: 6318-6322.
24. Yu S, Feng X, Shu T, Matano T, Hasegawa M, et al. (2008) Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 26: 6124-6131.
25. Zhang X, Cassis-Ghavami F, Eller M, Currier J, Slike BM, et al. (2007) Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J Virol 81: 7022-7033.
26. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ, (2008) Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 382: 226-238.
27. Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, et al. (2009) Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 15: 876-878.
28. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, et al. (2009) Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15: 873-875.
29. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, et al. (2010) Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28: 1932-1941.
30. Santra S, Sun Y, Korioth-Schmitz B, Fitzgerald J, Charbonneau C, et al. (2009) Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27: 5837-5845.
31. Muruve DA, (2004) The innate immune response to adenovirus vectors. Hum Gene Ther 15: 1157-1166.
32. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A, (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
33. Akridge RE, Oyafuso LK, Reed SG, (1994) IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J Immunol 153: 5782-5789.
34. Daftarian MP, Diaz-Mitoma F, Creery WD, Cameron W, Kumar A, (1995) Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus-infected individuals is associated with altered proliferative responses to recall antigens. Clin Diagn Lab Immunol 2: 712-718.
35. Alter G, Kavanagh D, Rihn S, Luteijn R, Brooks D, et al. (2010) IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J Clin Invest 120: 1905-1913.
36. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12: 1301-1309.
37. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, et al. (2006) Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203: 2461-2472.
38. Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, et al. (2009) IL-10 is upregulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 114: 346-356.
39. Chatterjee A, Rathore A, Sivarama P, Yamamoto N, Dhole TN, (2008) Genetic Association of IL-10 Gene Promoter Polymorphism and HIV-1 Infection in North Indians. J Clin Immunol 29: 71-77.
40. Shin HD, Winkler C, Stephens JC, Bream J, Young H, et al. (2000) Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 97: 14467-14472.
41. Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB, (2008) IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 205: 533-541.
42. Farber JM, (1997) Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61: 246-257.
43. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, et al. (2001) Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108: 1331-1339.
44. Huang XL, Fan Z, Borowski L, Rinaldo CR, (2008) Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity. J Leukoc Biol 83: 1530-1540.
45. Lin FC, Peng Y, Jones LA, Verardi PH, Yilma TD, (2008) Incorporation of CD40 Ligand into the Envelope of Pseudotyped Single-Cycle Simian Immunodeficiency Viruses Enhances Immunogenicity. J Virol 83: 1216-1227.
46. Liu J, Yu Q, Stone GW, Yue FY, Ngai N, et al. (2008) CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 26: 4062-4072.
47. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U, (1997) The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol 109: 54-58.
48. Zavala F, Rimaniol AC, Boussin F, Dormont D, Bach JF, et al. (1995) HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes. J Immunol 155: 2784-2793.
49. Promadej-Lanier N, Srinivasan P, Curtis K, Adams DR, Kim C, et al. (2008) Systemic and mucosal immunological responses during repeated mucosal SHIV(162P3) challenges prior to and following infection in pigtailed macaques. Virology 375: 492-503.
50. Crowe SM, Lopez A, (1997) GM-CSF and its effects on replication of HIV-1 in cells of macrophage lineage. J Leukoc Biol 62: 41-48.
51. Hammer SM, Gillis JM, Pinkston P, Rose RM, (1990) Effect of zidovudine and granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus replication in alveolar macrophages. Blood 75: 1215-1219.
52. Kedzierska K, Maerz A, Warby T, Jaworowski A, Chan H, et al. (2000) Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages. Aids 14: 1739-1748.
53. Armstrong WS, Kazanjian P, (2001) Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2. Clin Infect Dis 32: 766-773.
54. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198: 1482-1490.
55. Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, et al. (2009) Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 27: 243-249.
56. Calcedo R, Vandenberghe LH, Roy S, Somanathan S, Wang L, et al. (2009) Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 83: 2623-2631.
57. Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, et al. (2004) Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78: 11434-11438.
58. Yang C, Li M, Limpakarnjanarat K, Young NL, Hodge T, et al. (2003) Polymorphisms in the CCR5 coding and noncoding regions among HIV type 1-exposed, persistently seronegative female sex-workers from Thailand. AIDS Res Hum Retroviruses 19: 661-665.